Orforglipron
vs Semaglutide.
Compare FDA-approved Foundayo and Wegovy by pill and injection forms, molecular class, label results, approved uses, and the limits of separate trials.
Also searched as Foundayo vs Wegovy · orforglipron vs semaglutide · weight-loss pill comparison
What is the difference?
Foundayo and Wegovy are FDA-approved US weight-management products that activate the GLP-1 receptor, but they are not the same kind of drug and have not been compared in a randomized head-to-head trial. Foundayo contains orforglipron, a once-daily non-peptide small-molecule tablet. Wegovy contains the peptide semaglutide and its current US label includes both a once-daily 25 mg tablet and once-weekly injections. The Foundayo label reports about 11.1% mean weight reduction at 72 weeks for its highest approved equivalent-dose group, while the Wegovy tablet label reports 13.6% at 64 weeks. Those values come from separate protocols and do not prove that either product is superior.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Orforglipron
FDA-approved prescription drug
- Route
- Oral
- Registry
- Dedicated medicine evidence record
- Sponsor
- Lilly USA, LLC
Semaglutide
FDA-approved prescription drug
- Route
- Subcutaneous and oral
- Registry
- Dedicated medicine evidence record
- Sponsor
- Novo Nordisk Inc.
Orforglipron vs Semaglutide: how direct is the evidence?
No participant in the cited sources was randomized between Orforglipron and Semaglutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Orforglipron
Non-peptide small-molecule GLP-1 receptor agonist
- Route
- Oral
- Stage
- NDA 220934 approved product record
- Status
- FDA-approved prescription drug
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialSemaglutide
GLP-1 receptor agonist
- Route
- Subcutaneous and oral
- Stage
- NDA 215256 approved product record
- Status
- FDA-approved prescription drug
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
Outside this 13-program snapshot
This comparison uses an approved-medicine record here. A blank is a scope boundary, not evidence that no clinical trial or trial history exists.
Open the bounded clinical trial finder →Outside this 13-program snapshot
This comparison uses an approved-medicine record here. A blank is a scope boundary, not evidence that no clinical trial or trial history exists.
Open the bounded clinical trial finder →Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Orforglipron
Non-peptide small-molecule GLP-1 receptor agonist
- Route
- Oral
- Stage
- NDA 220934 approved product record
- Status
- FDA-approved prescription drug
- Featured trial anchors
- NDA 220934
Semaglutide
GLP-1 receptor agonist
- Route
- Subcutaneous and oral
- Stage
- NDA 215256 approved product record
- Status
- FDA-approved prescription drug
- Featured trial anchors
- NDA 215256
Compare the field, then read the limit.
This is no longer a simple pill-versus-shot comparison because the current Wegovy label includes oral and injected presentations. A useful comparison must first identify the exact Wegovy form, then separate molecular class, schedule, approved uses, study population, duration, dose escalation, analysis method, and placebo response. The available records can describe those fields and current US approval. They cannot predict an individual result, substitute one presentation for another, or turn unrelated label studies into a direct efficacy ranking.
| Field | Orforglipron | Semaglutide | How to interpret it |
|---|---|---|---|
| Molecular identity | Non-peptide small-molecule GLP-1 receptor agonist | Peptide GLP-1 receptor agonist | A shared receptor target does not make orforglipron a peptide or make the two active ingredients interchangeable. |
| Approved forms and schedule | Once-daily oral FOUNDAYO tablets | Once-daily 25 mg WEGOVY tablets and once-weekly WEGOVY injections | The Wegovy brand now spans two routes, so every comparison must name the exact presentation rather than treating the brand as one uniform regimen. |
| Weight-evidence anchor | About 11.1% at 72 weeks in the highest approved equivalent-dose group | 13.6% at 64 weeks in the 25 mg tablet study; injection studies remain separate | Different trials, durations, dose plans, analyses, and placebo responses prevent a valid numerical winner claim. |
| Current US record | FOUNDAYO under NDA 220934, approved April 1, 2026 | WEGOVY under NDA 215256, with product-specific labeled uses | Both are approved products, but approval attaches to the exact application, formulation, indication, company, and label. |
| Direct comparison | No randomized arm against Wegovy | No randomized arm against Foundayo | Relative efficacy, tolerability, adherence, preference, and individual suitability remain unresolved without a common protocol. |
Why the headline numbers do not name a winner.
Foundayo Trial 1 followed adults without diabetes for 72 weeks and the approved-label table reports an 11.1% mean change for the highest equivalent-dose group versus 2.1% with placebo. Wegovy Study 7 followed adults without diabetes for 64 weeks and reports 13.6% for the 25 mg tablet versus 2.4% with placebo. Wegovy injection studies use their own durations, doses, populations, and results. The products did not share randomization, so subtracting any two percentages would create a comparison that neither label tested.
Keep the comparison honest.
- 01
Identify whether a Wegovy claim concerns the 25 mg tablet or an injection before comparing route, schedule, result, warning, indication, or access.
- 02
Attach each percentage to its exact label study, population, duration, dose plan, placebo response, and analysis rather than subtracting separate trial averages.
- 03
Treat FOUNDAYO and WEGOVY as exact FDA-approved products, while rejecting any compounded, imported, or online item that borrows either label by ingredient name alone.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →